Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt

Lung Diseases: early-phase trial registry

10 of 32 indexed Lung Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #477 of 28,707 conditions by registered trial count.

32 US clinical trials · 10 currently recruiting · #477 of 28,707 conditions by registered trial count

Lung Diseases: 32 US clinical trials tracked, 10 recruiting.

Lung Diseases is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 3 of these trials.

Enrollment posture brief

Registry condition lung-diseases

OPEN 10 | RECR 31% | LATE 3 | EARLY 6 | RANK #477 | SPON 3

Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)

Acute Respiratory Distress S43.8%Cardiac Arrest37.5%Lung Diseases (this)31%Astigmatism28.1%Cardiovascular Risk Factor21.9%
Open-enrollment share among volume-matched conditions near Lung Diseases

Lung Diseases lists 10 open slots (31% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Diseases is recruiting below its size-band peers.

    10 of 32 indexed trials (31.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Diseases trials is spread across many organizations.

    Johns Hopkins University accounts for 3 of 32 trials (9.4%). 26 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Diseases enrolment sits around 263 participants.

    Median target enrolment is 263 among the 32 trials that report a genuine target (sentinel values excluded). 6 of those (18.8%) plan for fewer than 100 participants.

  4. Lung Diseases splits between interventional and observational designs.

    18 interventional and 14 observational studies make up this index (56.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 25Phase 33

Open and recent trials

32 total, page 1 of 1

RECRUITING 4,000 participants

American Lung Association (ALA) Lung Health Cohort

Johns Hopkins University

NCT04543461

RECRUITING 3,000 participants

Real World Registry for Use of the Ion Endoluminal System

Intuitive Surgical

NCT06004440

RECRUITING 2,000 participants

Cough Capture as a Portal Into the Lung

Albert Einstein College of Medicine

NCT05854563

RECRUITING 1,000 participants

Deep Functional Phenotyping of the ALA Lung Health Cohort

Johns Hopkins University

NCT06177717

RECRUITING NA 460 participants

Housing, Environment, And Living Conditions for Transformed Health

University of Alabama at Birmingham

NCT06925373

RECRUITING 250 participants

Data Collection Using Eko Digital Devices in a Clinical Setting

Eko Devices

NCT07227376

RECRUITING 100 participants

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

University of Miami

NCT06494033

RECRUITING 100 participants

Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research

Baylor Research Institute

NCT04664192

RECRUITING Phase 2 45 participants

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Dana-Farber Cancer Institute

NCT05922761

RECRUITING Phase 2 20 participants

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Pulmovant

NCT07333183

ACTIVE NOT RECRUITING 4,000 participants

Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)

Massachusetts General Hospital

NCT00006496

ACTIVE NOT RECRUITING 750 participants

Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting

Eko Devices

NCT07360522

ACTIVE NOT RECRUITING 600 participants

Gene Modifiers of Cystic Fibrosis Lung Disease

University of North Carolina, Chapel Hill

NCT00037765

ACTIVE NOT RECRUITING NA 365 participants

Clinical Utility for Ion Endoluminal System

Intuitive Surgical

NCT03893539

ACTIVE NOT RECRUITING Phase 2 135 participants

A Study of Mosliciguat in PH-ILD

Pulmovant

NCT06635850

ACTIVE NOT RECRUITING NA 130 participants

Aventus Thrombectomy System Pulmonary Embolism Clinical Study

Inquis Medical

NCT05907564

ACTIVE NOT RECRUITING Phase 2 19 participants

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

H. Lee Moffitt Cancer Center and Research Institute

NCT03598309

COMPLETED 1,256 participants

Prospective Investigation of Pulmonary Embolism Diagnosis III

George Washington University

NCT00241826

COMPLETED Phase 3 1,105 participants

Apnea Positive Pressure Long-Term Efficacy Study

Stanford University

NCT00051363

COMPLETED 959 participants

Stress, Environment, and Genetics in Urban Children With Asthma

Brigham and Women's Hospital

NCT00269256

COMPLETED 700 participants

Prevalence of Sleep-Disordered Breathing in Children

Milton S. Hershey Medical Center

NCT00022789

COMPLETED Phase 2 405 participants

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Pfizer

NCT00808288

COMPLETED Phase 3 403 participants

Study of Acid Reflux in Asthma

Johns Hopkins Bloomberg School of Public Health

NCT00069823

COMPLETED NA 263 participants

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents

San Diego State University

NCT00233168

COMPLETED NA 203 participants

Environmental Tobacco Smoke Exposure Reduction in High-Risk Preteens

San Diego State University

NCT00217893

COMPLETED 145 participants

Behavioral Interventions for Control of TB

Columbia University

NCT00005739

COMPLETED NA 139 participants

Influence of Data Collection Mode on Self-Report Validity of Asthma Therapy Adherence

Johns Hopkins University

NCT00233233

COMPLETED Phase 3 130 participants

Randomized Controlled Trial of Exercise Training in Patients With COPD

US Department of Veterans Affairs

NCT00012792

COMPLETED NA 100 participants

Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction

University of California, Los Angeles

NCT01126047

COMPLETED NA 95 participants

Asthma Data Innovation Demonstration Project

David Van Sickle

NCT02162576

COMPLETED NA 35 participants

Palliative Care Coaching for Families With Rare Advanced Lung Diseases

West Virginia University

NCT03813667

COMPLETED Phase 1 15 participants

Combination Paclitaxel, Carboplatin and Temozolomide

New Mexico Cancer Research Alliance

NCT00249964

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 3

Named interventions

Most-linked intervention names on Lung Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dry Powder Inhaler Device
2 trials
Eko digital stethoscopes Device
2 trials
Placebo Drug
2 trials
Placebo proton pump inhibitor Drug
1 trials
Propeller Health intervention Device
1 trials
Combination Treatment - Cohort 4 Drug
1 trials
Combination Treatment - Cohort 3 Drug
1 trials
Combination Treatment - Cohort 2 Drug
1 trials

US sites by state

Facility locations filed on Lung Diseases trials. A trial with sites in several states counts in each.

Florida 10 trials
California 10 trials
New York 8 trials
Massachusetts 8 trials
North Carolina 7 trials
Michigan 7 trials
Texas 6 trials
Illinois 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Diseases page

32 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Diseases condition card totals 32 registered trials; most-linked intervention Dry Powder Inhaler; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.